MetaCap

Assembly Biosciences (ASMB) vs Kamada (KMDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kamada (KMDA) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 14.7% versus a loss of 42.4%. Over five years, KMDA leads with a +22.7% price change compared with -21.3% for ASMB. Assembly Biosciences is the larger company by market cap ($454.4 million vs $446.8 million), about 1.0 times the size.

On valuation, Kamada trades at a lower trailing P/E (20.4x vs 29.6x for Assembly Biosciences). Kamada pays a dividend yielding 7.24%, while Assembly Biosciences does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -8.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASMB-42.36%KMDA+14.67%
+42%-6%-54%
Nov 21, 20251 yearNov 20, 2026
ASMB-19.60%KMDA+38.21%
+65%-5%-75%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASMB versus KMDA key metrics
MetricASMBKMDA
Share price$22.19$7.74
Market cap$454.39M$446.85M
1-day change-1.38%-1.15%
YTD return-34.75%+9.63%
1-year return-42.36%+14.67%
5-year return-21.31%+22.66%
P/E ratio (TTM)29.5920.37
Forward P/E—13.34
EPS (TTM)$0.75$0.38
Dividend yield0.00%7.24%
Annual dividend$0.00$0.56
Revenue (latest FY)$72.30M$180.46M
Revenue growth (YoY)+153.52%+12.12%
Net income (latest FY)$-6.12M$20.20M
Gross margin—42.34%
Operating margin-16.76%14.54%
Net margin-8.47%11.19%
52-week high$39.65$9.35
52-week low$19.20$6.63
Distance from 52-week high-44.04%-17.22%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+130.73%+77.65%
Average volume309.38K121.87K
Shares outstanding20.48M57.73M
Employees73462
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KMDA has outperformed ASMB by 57.0 percentage points over the past year.
  • Assembly Biosciences trades at a higher earnings multiple (29.6x vs 20.4x trailing P/E).
  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
  • Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -8.5 cents for Assembly Biosciences.
  • Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs +12.12%).

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

ASMB vs KMDA FAQ

Which is bigger, Assembly Biosciences or Kamada?

Assembly Biosciences (ASMB) is larger, with a market capitalization of $454.39M compared with $446.85M for Kamada (KMDA).

Which stock has performed better over the past year, ASMB or KMDA?

KMDA returned +14.67% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ASMB or KMDA?

KMDA has the lower trailing P/E at 20.4, versus 29.6 for ASMB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Assembly Biosciences or Kamada?

Kamada pays a dividend yielding 7.24%, while Assembly Biosciences does not currently pay a regular dividend.

Are Assembly Biosciences and Kamada in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons